에 대한 최신 뉴스 MakeMyTrip (NASDAQ:MMYT) 주식

MakeMyTrip

MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.

Large Cap

News

Movers

Trading Ideas

AFRM

FCNCA

KNTK

MEDP

MMYT

REGN

SMCI

SMMT

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 서밋 테라퓨틱스(NASDAQ:SMMT)의 주가는 씨티그룹이 주식을 매수에서 중립으로 하향 조정했으나 목표 주가를 19달러에서 23달러로 상향 조정한 후 14.37% 하락했다.

리제네론과 슈퍼 마이크로는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 23일-9월 27일)

MakeMyTrip Ltd

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares fell 14.37% last week after Citigroup downgraded the stock from <a href="https://www.benzinga.com/quote/smmt/analyst-ratings" target="_blank" rel="noreferrer noopener">Buy to Neutral</a> but raised its price target from $19 to $23.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) stock plummeted 12.46%.</li>
<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) stock fell 9.37% after Jefferies downgraded the stock from Buy to Hold and <a href="https://www.benzinga.com/quote/medp/analyst-ratings" target="_blank" rel="noreferrer noopener">cut its price target from $415 to $345</a>.</li>
<li>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) stock lost 8.94% last week after Leerink Partners <a href="https://www.benzinga.com/quote/regn/analyst-ratings" target="_blank" rel="noreferrer noopener">downgraded it</a> from Outperform to Market Perform and lowered its price target from $1,175 to $1,077.</li>
<li>Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) shares dived 8.74% after the company guided <a href="https://www.benzinga.com/pressreleases/24/09/b41024786/global-payments-shares-updated-strategy-and-medium-term-outlook-at-investor-conference" target="_blank" rel="noreferrer noopener">FY25 EPS growth below estimates</a>, and multiple firms downgraded the stock and<a href="https://www.benzinga.com/quote/gpn/analyst-ratings" target="_blank" rel="noreferrer noopener"> cut their respective price targets</a>.</li>
<li>Affirm Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) stock lost 8.39% last week. There was no company-specific news to justify the price loss.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares dipped 8.21% following a report indicating the company is being probed by the Department of Justice following an August short <a href="https://www.benzinga.com//node/41052423" target="_blank" rel="noreferrer noopener">report from</a><a href="https://www.benzinga.com//node/41052423" target="_blank" rel="noreferrer noopener"> Hindenburg Research</a>.</li>
<li>TechnipFMC plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) stock fell 6.10% amid reports suggesting Saudi Arabia may raise crude oil output.</li>
<li>First Citizens BancShares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) stock lost 6.09% last week after Wedbush analyst <a href="https://www.benzinga.com/quote/fcnca/analyst-ratings" target="_blank" rel="noreferrer noopener">downgraded the stock</a> from Outperform to Neutral and lowered the price target from $2,450 to $2,150.</li>
<li>ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) stock fell 5.93% from pressure following the DOJ&#8217;s Carahsoft investigation.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/41082440/chinese-stocks-dominate-jd-com-and-temu-parent-pdd-are-among-top-10-large-cap-gainers-last-week-se" target="_blank" rel="noreferrer noopener">Chinese Stocks Dominate &#8211; JD.com And Temu Parent PDD Are Among Top 10 Large Cap Gainers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Company

Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?

<h3>Gainers</h3>
<ul>
<li>Gaotu Techedu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOTU#NYSE">GOTU</a>) stock increased by 26.6% to $3.69 during Thursday's regular session. The company's market cap stands at $956.4 million. </li>
<li>Fenbo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEBO#NASDAQ">FEBO</a>) stock increased by 26.6% to $6.14. The company's market cap stands at $67.9 million. </li>
<li>Jianzhi Education Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>) stock increased by 24.2% to $1.06. The company's market cap stands at $21.3 million. </li>
<li>TAL Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) stock increased by 23.25% to $10.26. The market value of their outstanding shares is at $6.1 billion. </li>
<li>Uxin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) shares moved upwards by 22.97% to $2.89. The market value of their outstanding shares is at $543.1 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Studio City Intl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSC#NYSE">MSC</a>) shares rose 21.39% to $7.66. The market value of their outstanding shares is at $1.4 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alta Global Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) stock fell 15.4% to $1.76 during Thursday's regular session. The market value of their outstanding shares is at $18.1 million. </li>
<li>Digital Brands Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) shares decreased by 13.08% to $0.35. The company's market cap stands at $1.1 million. </li>
<li>Golden Sun Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSUN#NASDAQ">GSUN</a>) shares fell 11.43% to $6.2. The market value of their outstanding shares is at $12.2 million. </li>
<li>Genius Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares fell 9.78% to $0.95. The company's market cap stands at $20.5 million. </li>
<li>MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) shares fell 9.22% to $96.99. The market value of their outstanding shares is at $10.6 billion. </li>
<li>Thunder Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) stock fell 8.23% to $0.48. The market value of their outstanding shares is at $33.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIEV

DBGI

FEBO

GSX Techedu Inc. American Depositary Shares

GOTU

GSUN

UXIN

12 Consumer Discretionary Stocks Moving In Thursday's Intraday Session

Analysts' ratings for MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $105.5, a high estimate of $115.00, and a low estimate of $95.00. Witnessing a positive shift, the current average has risen by 12.23% from the previous average price target of $94.00.
<img src="https://www.benzinga.com/files/images/story/2024/1724760018_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of MakeMyTrip by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sachin Salgaonkar</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Vijit Jain</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Sachin Salgaonkar</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Sachin Salgaonkar</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$88.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to MakeMyTrip. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MakeMyTrip compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for MakeMyTrip's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of MakeMyTrip's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MMYT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MakeMyTrip analyst ratings.</a>
<h2>Unveiling the Story Behind MakeMyTrip</h2>
MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.
<h3>Financial Milestones: MakeMyTrip's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: MakeMyTrip displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 29.37%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: MakeMyTrip's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 8.26%, the company may face hurdles in effective cost management.
Return on Equity (ROE): MakeMyTrip's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.87%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.24%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.2.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Demystifying MakeMyTrip: Insights From 4 Analyst Reviews

B of A Securities analyst Sachin Salgaonkar maintains MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) with a Buy and raises the price target from $100 to $112.

Price Target

B of A Securities Maintains Buy on MakeMyTrip, Raises Price Target to $112

MakeMyTrip's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NYSE">MMYT</a>) short percent of float has fallen 28.07% since its last report. The company recently reported that it has 2.67 million shares sold short, which is 4.69% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>MakeMyTrip Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721923218_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for MakeMyTrip has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing MakeMyTrip's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, MakeMyTrip's peer group average for short interest as a percentage of float is 7.38%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into MakeMyTrip's Recent Short Interest

Citigroup analyst Vijit Jain maintains MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) with a Buy and raises the price target from $93 to $115.

Citigroup Maintains Buy on MakeMyTrip, Raises Price Target to $115

B of A Securities analyst Sachin Salgaonkar maintains MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) with a Buy and raises the price target from $95 to $100.

B of A Securities Maintains Buy on MakeMyTrip, Raises Price Target to $100

Shares of Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) fell sharply during Tuesday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/news/earnings/24/07/39908857/comcasts-q2-earnings-studios-and-theme-parks-pull-revenue-lower-broadband-and-video-subs-fall">second-quarter sales results</a>.
Comcast reported second-quarter revenue decline of 2.7% year-over-year to $29.69 billion, missing the analyst consensus estimate of $30.02 billion.The company reported adjusted EPS of $1.21, beating analyst consensus estimates of $1.12, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Comcast shares declined 6.1% to $37.12 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares jumped 529% to $10.19 after the company announced that the U.S. Patent and Trademark Office granted it U.S. Patent No. 12,036,248 for the treatment of atopic dermatitis.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) jumped 148% to $2.6299 after the company announced it advanced into the second cohort and commenced dosing for the Pharmacokinetics Study of AD04 for alcohol use disorder.</li>
<li>Salarius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) gained 111% to $3.2540.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares climbed 67% to $0.2390.</li>
<li>Smart for Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMFL#NASDAQ">SMFL</a>) rose 45% to $2.7950.</li>
<li>Dermata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) gained 43% to $2.41.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) jumped 36.5% to $4.60.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) gained 33.5% to $0.6385 after jumping around 20% on Monday.</li>
<li>Frequency Electronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) shares climbed 30% to $13.11 following fourth-quarter earnings. Also, the company declared a $1.00 special cash dividend.</li>
<li>Mammoth Energy Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TUSK#NASDAQ">TUSK</a>) gained 26% to $4.42 after the company announced its subsidiary, Cobra Acquisitions, entered into a release and settlement agreement with the Puerto Rico Electric Power Authority.</li>
<li>iClick Interactive Asia Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLK#NASDAQ">ICLK</a>) rose 23.5% to $2.05.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) jumped 19.3% to $2.90.</li>
<li>Milestone Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#NYSE">MLSS</a>) gained 17.5% to $1.02 after the company announced the Medicare price assignment for its CompuFlo Epidural System.</li>
<li>Staffing 360 Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) gained 16% to $2.1493.</li>
<li>Kiniksa Pharmaceuticals International, plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>) rose 16% to $24.81 after the company reported better-than-expected second-quarter sales results and raised its FY24 net product revenue guidance.</li>
<li>Aeva Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NYSE">AEVA</a>) gained 15.1% to $3.6713.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) jumped 12.7% to $333.02 following second-quarter earnings.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) gained 11.8% to $12.34.</li>
<li>PureCycle Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) rose 11.8% to $6.90.</li>
<li>MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) gained 11.1% to $561.96 following better-than-expected second-quarter financial results.</li>
<li>Crown Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) rose 8.5% to $84.04 after the company reported better-than-expected second-quarter earnings and raised its FY24 EPS guidance above estimates.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) gained 8% to $96.75 following better-than-expected quarterly earnings.</li>
<li>Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) gained 8% to $16.51 as the company released preliminary second quarter 2024 financial results and signed a definitive agreement to acquire Rotech Healthcare for $1.36 billion in cash.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares surged 8% to $8.15. Mesoblast recently started enrollment in Phase 3 trial of Rexlemestrocel-L for chronic low back pain.</li>
<li>Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) climbed 7.7% to $86.19 after the company reported better-than-expected second quarter financial results and revised its FY24 adjusted EPS guidance above estimates.</li>
<li>Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) gained 7.4% to $269.35 after the company reported better-than-expected second quarter earnings.</li>
<li>GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) gained 6.4% to $173.21 after the company reported better-than-expected second quarter adjusted EPS and raised its FY24 outlook.</li>
<li>SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) rose 6% to $0.2390 after the company reported second-quarter financial results.</li>
<li>Zions Bancorporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) gained 5.4% to $52.12 after posting better-than-expected quarterly results on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares dipped 65% to $1.50 after the company announced its phase 3 OnTarget trial results for Crofelemer did not meet its primary endpoint.</li>
<li>TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) dipped 62.2% to $0.2999 after the company announced a proposed public offering.</li>
<li>Fly-E Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) tumbled 59.2% to $2.60.</li>
<li>MIRA Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares dipped 50.3% to $2.4636. MIRA Pharmaceuticals shares jumped 627% on Monday after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares fell 38.3% to $3.1851 after surging 228% on Monday.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) dipped 32.4% to $0.0250.</li>
<li>PS International Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) fell 32.2% to $1.83.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) fell 31.1% to $0.3440.</li>
<li>Cellectar Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) dipped 26.2% to $2.23. The company announced results from its CLOVER WaM pivotal study evaluating iopofosine I 131.</li>
<li>Crown LNG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) fell 23% to $0.77.</li>
<li>Castellum, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTM#NYSE">CTM</a>) fell 20% to $0.1594. Castellum recently announced a new strategic alliance with Krilla Kaleiwahea.</li>
<li>Netcapital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>) fell 17.3% to $0.0926 after gaining around 8% on Monday.</li>
<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares declined 16.6% to $364.00 after the company reported mixed second-quarter financial results and narrowed its FY24 revenue guidance with its midpoint below estimates.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) dipped 15.2% to $16.48.</li>
<li>United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) fell 13.2% to $126.04 after the company reported worse-than-expected quarterly financial results.</li>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) shares fell 10% to $0.4479 after gaining over 55% on Monday.</li>
<li>NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) shares fell 9.5% to $256.55 following mixed second-quarter earnings.</li>
<li>New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) dipped 9.2% to $23.28.</li>
<li>PACCAR Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) fell 8.4% to $99.92 after the company reported worse-than-expected second-quarter financial results.</li>
<li>A. O. Smith Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>) declined 8.4% to $81.30. The company reported second-quarter financial results.</li>
<li>WEBTOON Entertainment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) dipped 7.7% to $22.00.</li>
<li>Polaris Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) declined 7.2% to $76.23 after the company reported worse-than-expected second-quarter financial results and cut its guidance.</li>
<li>Archrock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) shares declined 6.9% to $21.76. Archrock commenced public offering of 11 million shares of its common stock and announced plans to acquire Total Operations and Production Services for $983 million in cash and stock.</li>
<li>General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) fell 6.1% to $46.52 after the company reported second-quarter financial results. Also, the company announced that it delayed its 2024 Buick EV and pushed its EV pickup plant opening to 2026.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39907957/microsoft-to-rally-around-10-here-are-10-top-analyst-forecasts-for-monday">Microsoft To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Intraday Update

ADIL

AEVA

AROC

ATPC

AZTR

CGBS

CLRB

CMAX

CMCSA

DRMA

EFSH

FEIM

FLYE

FTEL

ICLK

JAGX

KNSA

MESO

MIRA

MLSS

MSCI

NCPL

NUKK

NXPI

PCAR

PSIG

RNAZ

SLNA

SLRX

SMFL

SOAR

SPOT

STAF

TUSK

WBTN

XCUR

ZION

Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Tuesday.
Shares of Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) rose sharply during Tuesday's session after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/07/39907956/life-science-giant-danahers-q2-earnings-beat-estimates-on-sustained-positive-momentum-in-bioprocess">second quarter earnings</a>.
Danaher's second quarter sales decreased 3% year-over-year to $5.743 billion, beating the consensus of $5.59 billion. Danaher reported second-quarter adjusted EPS of $1.72, beating the consensus of $1.57, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Danaher shares gained 7.4% to $269.35 on Tuesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Kiniksa Pharmaceuticals International, plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>) shares jumped 16% to $24.81 after the company reported better-than-expected second-quarter sales results and raised its FY24 net product revenue guidance.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) gained 12.7% to $333.02 following second-quarter earnings.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) surged 11.8% to $12.34.</li>
<li>PureCycle Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) gained 11.8% to $6.90.</li>
<li>KKR Real Estate Finance Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KREF#NYSE">KREF</a>) surged 11.2% to $11.22 following second-quarter results.</li>
<li>MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) shares jumped 11.1% to $561.96 following better-than-expected second-quarter financial results.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) gained 10.3% to $66.27.</li>
<li>Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) gained 9% to $29.48. HC Wainwright &amp; Co. analyst Patrick Trucchio initiated coverage on Beam Therapeutics with a Buy rating and announced a price target of $80.</li>
<li>Iridium Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>) rose 8.5% to $28.11 after the company reported better-than-expected second-quarter EPS results.</li>
<li>Crown Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) gained 8.5% to $84.04 after the company reported better-than-expected second-quarter earnings and raised its FY24 EPS guidance above estimates.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) climbed 8% to $96.75 following better-than-expected quarterly earnings.</li>
<li>Inter Parfums, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPAR#NASDAQ">IPAR</a>) gained 8% to $137.34 after the company reported better-than-expected expected sales.</li>
<li>Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) rose 8% to $16.51 as the company released preliminary second quarter 2024 financial results and signed a definitive agreement to acquire Rotech Healthcare for $1.36 billion in cash.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares gained 8% to $8.15. Mesoblast recently started enrollment in Phase 3 trial of Rexlemestrocel-L for chronic low back pain.</li>
<li>Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) gained 7.7% to $86.19 after the company reported better-than-expected second quarter financial results and revised its FY24 adjusted EPS guidance above estimates.</li>
<li>Park National Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRK#NYSE">PRK</a>) gained 7.4% to $182.78 following upbeat quarterly earnings.</li>
<li>Wheels Up Experience Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UP#NYSE">UP</a>) gained 7.1% to $3.46.</li>
<li>GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) shares surged 6.4% to $173.21 after the company reported better-than-expected second quarter adjusted EPS and raised its FY24 outlook.</li>
<li>SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) gained 6% to $0.2390 after the company reported second-quarter financial results.</li>
<li>Hims &amp; Hers Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NASDAQ">HIMS</a>) gained 5.6% to $21.51.</li>
<li>e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) surged 5.5% to $178.95.</li>
<li>Zions Bancorporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) rose 5.4% to $52.12 after posting better-than-expected quarterly results on Monday.</li>
<li>Brown &amp; Brown, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) gained 5.2% to $97.99 following upbeat quarterly earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39907046/best-buy-kroger-and-2-other-stocks-insiders-are-selling">Best Buy, Kroger And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

Markets

BEAM

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IPAR

IRDM

KREF

Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday

WIIM

MakeMyTrip shares are trading higher following better-than-expected Q1 earnings.

MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) reported quarterly earnings of $0.39 per share which beat the analyst consensus estimate of $0.27 by 44.44 percent. This is a 30 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $243.658 million which beat the analyst consensus estimate of $242.186 million by 0.61 percent. This is a 22.88 percent increase over sales of $198.297 million the same period last year.

Earnings

Earnings Beats

MakeMyTrip Q1 2025 Adj EPS $0.39 Beats $0.27 Estimate, Sales $243.658M Beat $242.186M Estimate

MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) has outperformed the market over the past 10 years by 1.38% on an annualized basis producing an average annual return of 12.39%. Currently, MakeMyTrip has a market capitalization of $9.89 billion. 
Buying $100 In MMYT: If an investor had bought $100 of MMYT stock 10 years ago, it would be worth $330.98 today based on a price of $90.06 for MMYT at the time of writing.
<h3>MakeMyTrip's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721055654_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/12/24</td>
<td>$270.00</td>
<td>$41.4K</td>
<td>22.3K</td>
<td>171.2K</td>
</tr>
<tr>
<td>AMZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/12/24</td>
<td>$202.50</td>
<td>$26.1K</td>
<td>16.1K</td>
<td>45.2K</td>
</tr>
<tr>
<td>BABA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$75.00</td>
<td>$177.3K</td>
<td>10.6K</td>
<td>2.9K</td>
</tr>
<tr>
<td>RIVN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$14.00</td>
<td>$78.0K</td>
<td>7.9K</td>
<td>1.2K</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$70.00</td>
<td>$64.0K</td>
<td>12.3K</td>
<td>1.0K</td>
</tr>
<tr>
<td>WSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$130.00</td>
<td>$42.2K</td>
<td>38</td>
<td>59</td>
</tr>
<tr>
<td>MMYT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$90.00</td>
<td>$31.7K</td>
<td>174</td>
<td>32</td>
</tr>
<tr>
<td>UAA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$5.00</td>
<td>$135.0K</td>
<td>1.2K</td>
<td>25</td>
</tr>
<tr>
<td>GOTU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$6.00</td>
<td>$48.9K</td>
<td>1.2K</td>
<td>6</td>
</tr>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$165.00</td>
<td>$69.4K</td>
<td>20.3K</td>
<td>1</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding TSLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), we observe a call option sweep with bearish sentiment. It expires in 3 day(s) on July 12, 2024. Parties traded 122 contract(s) at a $270.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $41.4K, with a price of $340.0 per contract. There were 22307 open contracts at this strike prior to today, and today 171238 contract(s) were bought and sold. 
• For AMZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), we notice a call option sweep that happens to be bearish, expiring in 3 day(s) on July 12, 2024. This event was a transfer of 300 contract(s) at a $202.50 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $26.1K, with a price of $87.0 per contract. There were 16179 open contracts at this strike prior to today, and today 45272 contract(s) were bought and sold. 
• Regarding BABA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), we observe a call option sweep with bearish sentiment. It expires in 10 day(s) on July 19, 2024. Parties traded 799 contract(s) at a $75.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $177.3K, with a price of $222.0 per contract. There were 10629 open contracts at this strike prior to today, and today 2969 contract(s) were bought and sold. 
• For RIVN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>), we notice a put option trade that happens to be bearish, expiring in 38 day(s) on August 16, 2024. This event was a transfer of 1000 contract(s) at a $14.00 strike. The total cost received by the writing party (or parties) was $78.0K, with a price of $78.0 per contract. There were 7915 open contracts at this strike prior to today, and today 1260 contract(s) were bought and sold. 
• Regarding NKE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>), we observe a put option sweep with bullish sentiment. It expires in 73 day(s) on September 20, 2024. Parties traded 439 contract(s) at a $70.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $64.0K, with a price of $146.0 per contract. There were 12357 open contracts at this strike prior to today, and today 1097 contract(s) were bought and sold. 
• For WSM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>), we notice a put option sweep that happens to be bullish, expiring in 192 day(s) on January 17, 2025. This event was a transfer of 41 contract(s) at a $130.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $42.2K, with a price of $1030.0 per contract. There were 38 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. 
• For MMYT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>), we notice a call option trade that happens to be neutral, expiring in 129 day(s) on November 15, 2024. This event was a transfer of 25 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $31.7K, with a price of $1270.0 per contract. There were 174 open contracts at this strike prior to today, and today 32 contract(s) were bought and sold. 
• Regarding UAA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>), we observe a put option trade with neutral sentiment. It expires in 556 day(s) on January 16, 2026. Parties traded 3000 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $135.0K, with a price of $45.0 per contract. There were 1205 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• Regarding GOTU (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOTU#NYSE">GOTU</a>), we observe a call option sweep with bearish sentiment. It expires in 101 day(s) on October 18, 2024. Parties traded 699 contract(s) at a $6.00 strike. This particular call needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $48.9K, with a price of $70.0 per contract. There were 1218 open contracts at this strike prior to today, and today 6 contract(s) were bought and sold. 
• Regarding PDD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), we observe a call option sweep with bearish sentiment. It expires in 255 day(s) on March 21, 2025. Parties traded 64 contract(s) at a $165.00 strike. This particular call needed to be split into 29 different trades to become filled. The total cost received by the writing party (or parties) was $69.4K, with a price of $1085.0 per contract. There were 20345 open contracts at this strike prior to today, and today 1 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMZN

BABA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

RIVN

TSLA

10 Consumer Discretionary Stocks Whale Activity In Today's Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>B. Riley Securities raised the price target for Cinemark Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) from $16 to $27. B. Riley Securities analyst Eric Wold upgraded the stock from Neutral to Buy. Cinemark shares rose 1.7% to close at $21.73 on Friday. <a href="https://www.benzinga.com/quote/CNK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keefe, Bruyette &amp; Woods raised the price target for American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) from $265 to $280. Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintained an Outperform rating. American Express shares gained 0.3% to close at $235.63 on Friday. <a href="https://www.benzinga.com/quote/AXP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel boosted the price target for Ecolab Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) from $233 to $283. Stifel analyst Shlomo Rosenbaum upgraded the stock from Hold to Buy. Ecolab shares gained 1% to close at $238.19 on Friday. <a href="https://www.benzinga.com/quote/ECL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird increased Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) price target from $530 to $580. Baird analyst David Tarantino upgraded the stock from Neutral to Outperform. Domino&#8217;s shares fell 0.7% to close at $493.73 on Friday. <a href="https://www.benzinga.com/quote/DPZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. boosted the price target for Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) from $70 to $90. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. Insmed shares gained 12.9% to close at $70.00 on Friday. <a href="https://www.benzinga.com/quote/INSM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>TD Cowen slashed Stifel Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SF#NYSE">SF</a>) price target from $94 to $89. TD Cowen analyst Bill Katz downgraded the stock from Buy to Hold. Stifel Financial shares fell 1.2% to close at $82.41 on Friday. <a href="https://www.benzinga.com/quote/SF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel cut Procore Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) price target from $90 to $85. Stifel analyst Tom Roderick maintained a Buy rating. Procore Technologies shares gained 0.1% to close at $68.86 on Friday. <a href="https://www.benzinga.com/quote/PCOR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods raised Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) price target from $145 to $160. Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintained an Outperform rating. Discover Financial shares fell 2.4% to close at $128.89 on Friday. <a href="https://www.benzinga.com/quote/DFS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods cut Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) price target from $150 to $140. Keefe, Bruyette &amp; Woods analyst Vasundhara Govil maintained an Outperform rating. Global Payments shares fell 0.4% to close at $96.22 on Friday. <a href="https://www.benzinga.com/quote/GPN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) price target from $88 to $95. B of A Securities analyst Sachin Salgaonkar maintained a Buy rating. MakeMyTrip shares fell 3.2% to close at $85.95 on Friday. <a href="https://www.benzinga.com/quote/MMYT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/07/39659420/fear-greed-index-moves-to-neutral-zone-as-s-p-500-hits-record-high-after-friday-jobs-data">Fear &amp; Greed Index Moves To &#8216;Neutral&#8217; Zone As S&amp;P 500 Hits Record High After Friday Jobs Data</a>

INSM

PCOR

American Express To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday

B of A Securities analyst Sachin Salgaonkar maintains MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) with a Buy and raises the price target from $88 to $95.

B of A Securities Maintains Buy on MakeMyTrip, Raises Price Target to $95

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/05/24</td>
<td>$250.00</td>
<td>$40.9K</td>
<td>21.8K</td>
<td>243.5K</td>
</tr>
<tr>
<td>GM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/12/24</td>
<td>$47.00</td>
<td>$25.0K</td>
<td>572</td>
<td>2.8K</td>
</tr>
<tr>
<td>ZK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$22.50</td>
<td>$27.5K</td>
<td>394</td>
<td>2.0K</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$34.00</td>
<td>$1.6 million</td>
<td>275</td>
<td>1.3K</td>
</tr>
<tr>
<td>AMZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$190.00</td>
<td>$180.1K</td>
<td>2.7K</td>
<td>822</td>
</tr>
<tr>
<td>CMG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$62.00</td>
<td>$26.5K</td>
<td>1.1K</td>
<td>700</td>
</tr>
<tr>
<td>RIVN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$19.00</td>
<td>$25.7K</td>
<td>1.4K</td>
<td>413</td>
</tr>
<tr>
<td>ABNB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/12/24</td>
<td>$152.50</td>
<td>$39.8K</td>
<td>327</td>
<td>122</td>
</tr>
<tr>
<td>HZO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$25.00</td>
<td>$68.0K</td>
<td>138</td>
<td>100</td>
</tr>
<tr>
<td>MMYT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$90.00</td>
<td>$31.8K</td>
<td>218</td>
<td>32</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding TSLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), we observe a call option sweep with bullish sentiment. It expires in 1 day(s) on July 5, 2024. Parties traded 146 contract(s) at a $250.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $40.9K, with a price of $277.0 per contract. There were 21826 open contracts at this strike prior to today, and today 243517 contract(s) were bought and sold. 
• Regarding GM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), we observe a call option trade with neutral sentiment. It expires in 8 day(s) on July 12, 2024. Parties traded 432 contract(s) at a $47.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $58.0 per contract. There were 572 open contracts at this strike prior to today, and today 2886 contract(s) were bought and sold. 
• Regarding ZK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>), we observe a call option trade with bearish sentiment. It expires in 15 day(s) on July 19, 2024. Parties traded 500 contract(s) at a $22.50 strike. The total cost received by the writing party (or parties) was $27.5K, with a price of $55.0 per contract. There were 394 open contracts at this strike prior to today, and today 2025 contract(s) were bought and sold. 
• Regarding JD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), we observe a put option sweep with bearish sentiment. It expires in 106 day(s) on October 18, 2024. Parties traded 2217 contract(s) at a $34.00 strike. This particular put needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $1.6 million, with a price of $730.0 per contract. There were 275 open contracts at this strike prior to today, and today 1334 contract(s) were bought and sold. 
• For AMZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), we notice a call option trade that happens to be bearish, expiring in 22 day(s) on July 26, 2024. This event was a transfer of 160 contract(s) at a $190.00 strike. The total cost received by the writing party (or parties) was $180.1K, with a price of $1126.0 per contract. There were 2772 open contracts at this strike prior to today, and today 822 contract(s) were bought and sold. 
• For CMG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), we notice a call option trade that happens to be bearish, expiring in 22 day(s) on July 26, 2024. This event was a transfer of 100 contract(s) at a $62.00 strike. The total cost received by the writing party (or parties) was $26.5K, with a price of $265.0 per contract. There were 1195 open contracts at this strike prior to today, and today 700 contract(s) were bought and sold. 
• Regarding RIVN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>), we observe a call option sweep with bearish sentiment. It expires in 169 day(s) on December 20, 2024. Parties traded 161 contract(s) at a $19.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $25.7K, with a price of $160.0 per contract. There were 1443 open contracts at this strike prior to today, and today 413 contract(s) were bought and sold. 
• Regarding ABNB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), we observe a put option sweep with bearish sentiment. It expires in 8 day(s) on July 12, 2024. Parties traded 183 contract(s) at a $152.50 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $39.8K, with a price of $218.0 per contract. There were 327 open contracts at this strike prior to today, and today 122 contract(s) were bought and sold. 
• For HZO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>), we notice a call option trade that happens to be bearish, expiring in 106 day(s) on October 18, 2024. This event was a transfer of 100 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $68.0K, with a price of $680.0 per contract. There were 138 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For MMYT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>), we notice a call option sweep that happens to be neutral, expiring in 134 day(s) on November 15, 2024. This event was a transfer of 30 contract(s) at a $90.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $31.8K, with a price of $1060.0 per contract. There were 218 open contracts at this strike prior to today, and today 32 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABNB

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Consumer Discretionary sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/05/24</td>
<td>$250.00</td>
<td>$40.9K</td>
<td>21.8K</td>
<td>243.5K</td>
</tr>
<tr>
<td>GM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/12/24</td>
<td>$47.00</td>
<td>$25.0K</td>
<td>572</td>
<td>2.8K</td>
</tr>
<tr>
<td>ZK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$22.50</td>
<td>$27.5K</td>
<td>394</td>
<td>2.0K</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$34.00</td>
<td>$1.6 million</td>
<td>275</td>
<td>1.3K</td>
</tr>
<tr>
<td>AMZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$190.00</td>
<td>$180.1K</td>
<td>2.7K</td>
<td>822</td>
</tr>
<tr>
<td>CMG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$62.00</td>
<td>$26.5K</td>
<td>1.1K</td>
<td>700</td>
</tr>
<tr>
<td>RIVN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$19.00</td>
<td>$25.7K</td>
<td>1.4K</td>
<td>413</td>
</tr>
<tr>
<td>ABNB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/12/24</td>
<td>$152.50</td>
<td>$39.8K</td>
<td>327</td>
<td>122</td>
</tr>
<tr>
<td>HZO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$25.00</td>
<td>$68.0K</td>
<td>138</td>
<td>100</td>
</tr>
<tr>
<td>MMYT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$90.00</td>
<td>$31.8K</td>
<td>218</td>
<td>32</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For TSLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), we notice a call option sweep that happens to be bullish, expiring in 2 day(s) on July 5, 2024. This event was a transfer of 146 contract(s) at a $250.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $40.9K, with a price of $277.0 per contract. There were 21826 open contracts at this strike prior to today, and today 243517 contract(s) were bought and sold. 
• Regarding GM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), we observe a call option trade with neutral sentiment. It expires in 9 day(s) on July 12, 2024. Parties traded 432 contract(s) at a $47.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $58.0 per contract. There were 572 open contracts at this strike prior to today, and today 2886 contract(s) were bought and sold. 
• Regarding ZK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on July 19, 2024. Parties traded 500 contract(s) at a $22.50 strike. The total cost received by the writing party (or parties) was $27.5K, with a price of $55.0 per contract. There were 394 open contracts at this strike prior to today, and today 2025 contract(s) were bought and sold. 
• Regarding JD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), we observe a put option sweep with bearish sentiment. It expires in 107 day(s) on October 18, 2024. Parties traded 2217 contract(s) at a $34.00 strike. This particular put needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $1.6 million, with a price of $730.0 per contract. There were 275 open contracts at this strike prior to today, and today 1334 contract(s) were bought and sold. 
• Regarding AMZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), we observe a call option trade with bearish sentiment. It expires in 23 day(s) on July 26, 2024. Parties traded 160 contract(s) at a $190.00 strike. The total cost received by the writing party (or parties) was $180.1K, with a price of $1126.0 per contract. There were 2772 open contracts at this strike prior to today, and today 822 contract(s) were bought and sold. 
• For CMG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), we notice a call option trade that happens to be bearish, expiring in 23 day(s) on July 26, 2024. This event was a transfer of 100 contract(s) at a $62.00 strike. The total cost received by the writing party (or parties) was $26.5K, with a price of $265.0 per contract. There were 1195 open contracts at this strike prior to today, and today 700 contract(s) were bought and sold. 
• Regarding RIVN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>), we observe a call option sweep with bearish sentiment. It expires in 170 day(s) on December 20, 2024. Parties traded 161 contract(s) at a $19.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $25.7K, with a price of $160.0 per contract. There were 1443 open contracts at this strike prior to today, and today 413 contract(s) were bought and sold. 
• Regarding ABNB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), we observe a put option sweep with bearish sentiment. It expires in 9 day(s) on July 12, 2024. Parties traded 183 contract(s) at a $152.50 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $39.8K, with a price of $218.0 per contract. There were 327 open contracts at this strike prior to today, and today 122 contract(s) were bought and sold. 
• For HZO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>), we notice a call option trade that happens to be bearish, expiring in 107 day(s) on October 18, 2024. This event was a transfer of 100 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $68.0K, with a price of $680.0 per contract. There were 138 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• Regarding MMYT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>), we observe a call option sweep with neutral sentiment. It expires in 135 day(s) on November 15, 2024. Parties traded 30 contract(s) at a $90.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $31.8K, with a price of $1060.0 per contract. There were 218 open contracts at this strike prior to today, and today 32 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock&#39;s price, but are they really important?
Let&#39;s take a look at what these Wall Street heavyweights have to say about MakeMyTrip (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mmyt#NASDAQ">MMYT</a>) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
MakeMyTrip currently has an average brokerage recommendation of 1.36, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by seven brokerage firms. An ABR of 1.36 approximates between Strong Buy and Buy.
Of the seven recommendations that derive the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 71.4% and 14.3% of all recommendations.
Brokerage Recommendation Trends for MMYT
<img alt="Broker Rating Breakdown Chart for MMYT" class="chart" src="https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/MMYT_06052024.png" style="width:100%" title="" /> 
The ABR suggests buying MakeMyTrip, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five &quot;Strong Buy&quot; recommendations for every &quot;Strong Sell&quot; recommendation.
In other words, their interests aren&#39;t always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock&#39;s price movement.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock&#39;s near -term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABR
Although both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
Is MMYT a Good Investment?
Looking at the earnings estimate revisions for MakeMyTrip, the Zacks Consensus Estimate for the current year has increased 0.4% over the past month to $1.62.
Analysts&#39; growing optimism over the company&#39;s earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #1 (Strong Buy) for MakeMyTrip.
Therefore, the Buy-equivalent ABR for MakeMyTrip may serve as a useful guide for investors.
<a href="https://www.zacks.com/stock/news/2283876/wall-street-analysts-think-makemytrip-mmyt-is-a-good-investment-is-it?cid=CS-BENZ-FT-fundamental_analysis|average_broker_rating-2283876">To read this article on Zacks.com click here.</a>

Wall Street Analysts Think MakeMyTrip Is a Good Investment: Is It?

Shares of Lands&#8217; End, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) fell sharply during Wednesday's session following<a href="https://www.benzinga.com/quote/LE/earnings"> first-quarter results</a>.
Lands&#8217; End reported quarterly adjusted loss of 20 cents per share which beat the analyst consensus estimate of 26 cents per share. The company reported quarterly sales of $285.47 million which beat the analyst consensus estimate of $269.82 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Lands&#8217; End shares dipped 9.3% to $12.60 on Wednesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Actelis Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) shares jumped 512% to $2.88 after the company announced orders for cyber-hardened networking technology to be deployed at three US military bases.</li>
<li>Nuvve Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) shares jumped 150% to $1.42.</li>
<li>ENDRA Life Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares gained 82.2% to $0.1549. ENDRA Life Sciences shares dipped over 60% on Tuesday after the company announced the pricing of an $8 million public offering.</li>
<li>mF International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFI#NASDAQ">MFI</a>) gained 66.9% to $2.17 after jumping 38% on Tuesday.</li>
<li>Moving iMage Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#NASDAQ">MITQ</a>) gained 53.2% to $1.0750 after the company was awarded a multi-million dollar contract.</li>
<li>Siyata Mobile Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>) gained 52.5% to $2.1200 after the company announced a new partnership with JD Telecom.</li>
<li>WalkMe Ltd.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKME#NASDAQ">WKME</a>) gained 42.1% to $13.70 after the company announced it entered into a definitive agreement to be acquired by SAP.</li>
<li>Stitch Fix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) rose 34.9% to $3.6010 following better-than-expected third-quarter financial results.</li>
<li>XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) jumped 30% to $1.1877 after the company announced Mesa Air Group is the purchaser under a previously disclosed conditional purchase order with XTI Aircraft Company.</li>
<li>Unusual Machines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#NYSE">UMAC</a>) rose 27.2% to $1.9002.</li>
<li>Hywin Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYW#NYSE">HYW</a>) gained 24.9% to $0.7379.</li>
<li>China Liberal Education Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) rose 21.1% to $1.2710.</li>
<li>Multi Ways Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MWG#NYSE">MWG</a>) gained 19.4% to $0.5741.</li>
<li>Mynd.ai, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYND#NYSE">MYND</a>) rose 16.6% to $2.95.</li>
<li>Vir Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) gained 16.4% to $12.31 after the company announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart.</li>
<li>3D Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) gained 16% to $4.030 after the company received a multi-year purchase agreement with an estimated value of around a quarter-billion dollars.</li>
<li>Laird Superfood, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSF#NYSE">LSF</a>) gained 15.6% to $4.3350.</li>
<li>Verint Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) rose 15.3% to $32.54 after the company reported better-than-expected first-quarter financial results and issued strong FY25 guidance.</li>
<li>Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) shares rose 15.1% to $20.26 as the company reported better-than-expected second-quarter financial results.</li>
<li>Guidewire Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) gained 15% to $124.20 after the company reported better-than-expected third-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>United Natural Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) jumped 12.7% to $13.69 following upbeat quarterly earnings.</li>
<li>CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) gained 10.4% to $4.46.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) rose 10.2% to $19.57.</li>
<li>Bright Green Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) shares rose 8.2% to $0.3204 after gaining around 5% on Tuesday.</li>
<li>Ollie&#8217;s Bargain Outlet Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) gained 7.8% to $88.43 following better-than-expected first-quarter earnings.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) gained 6.8% to $78.68.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Concord Medical Services Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) fell 37.7% to $1.3099 after jumping 166% on Tuesday.</li>
<li>Barnes &amp; Noble Education, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNED#NYSE">BNED</a>) shares declined 35% to $0.2699.</li>
<li>MicroAlgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares dipped 33.2% to $8.02. MicoAlgo shares jumped around 670% on Tuesday after the company announced that it will jointly establish a micro-consciousness quantum research center with WiMi.</li>
<li>Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) declined 30.6% to $1.55 after the company announced a $2 million registered direct offering.</li>
<li>SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares fell 29.2% to $0.3236 after surging 75% on Tuesday.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) fell 24.7% to $138.91.</li>
<li>JIADE Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) fell 23% to $ 1.3450</li>
<li>Cue Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) fell 21.3% to $0.0486.</li>
<li>Volcon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) shares declined 21% to $0.1318 after the company announced a 1-for-100 reverse stock split.</li>
<li>SPAR Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRP#NASDAQ">SGRP</a>) fell 19.9% to $2.2668 after the company announced that it entered into a letter of intent to go private with Highwire Capital.</li>
<li>Power REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PW#NYSE">PW</a>) fell 19.8% to $0.9001.</li>
<li>FibroBiologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) dipped 19.3% to $7.27.</li>
<li>Adamas One Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JEWL#NASDAQ">JEWL</a>) dipped 18.8% to $ 0.3062.</li>
<li>Adlai Nortye Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANL#NASDAQ">ANL</a>) fell 17% to $5.17</li>
<li>Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares fell 16.4% to $3.75 after jumping around 67% on Tuesday.</li>
<li>Mind Medicine (MindMed) Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) shares fell 16.2% to $6.92 after declining 5% on Tuesday.</li>
<li>Ambac Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBC#NYSE">AMBC</a>) shares declined 15.6% to $14.53. Ambac Financial Group announced plans to acquire a majority stake in Beat Capital Partners.</li>
<li>Golden Heaven Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares fell 13.7% to $0.1938 after declining around 4% on Tuesday.</li>
<li>Fortuna Silver Mines Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSM#NYSE">FSM</a>) dipped 13.6% to $5.10 after the company announced a $150 million offering of convertible senior notes.</li>
<li>ThermoGenesis Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) shares declined 13.4% to $0.5534 after gaining over 10% on Tuesday.</li>
<li>Fresh2 Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares fell 11% to $0.3970 after gaining 13% on Tuesday.</li>
<li>COMPASS Pathways plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) shares fell 10.6% to $6.84.</li>
<li>MultiPlan Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>) declined 7.8% to $0.4342</li>
<li>DouYu International Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOYU#NASDAQ">DOYU</a>) fell 4.7% to $9.64 following first-quarter results.</li>
<li>Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) shares fell 4.3% to $115.11 after the company reported first-quarter earnings and announced a review of strategic alternatives for its Family Dollar business.</li>
<li>Brown-Forman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) fell 4% to $43.90 following mixed quarterly earnings.</li>
<li>Designer Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>) fell 3.9% to $8.40. The company, on Tuesday, reported first-quarter FY24 sales growth of 0.6% year-on-year to $746.596 million, beating the analyst consensus estimate of $741.630 million.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39184853/jim-cramer-energy-transfer-has-done-a-very-good-job-recommends-selling-this-tech-stock">Jim Cramer: Energy Transfer Has &#8216;Done A Very Good Job,&#8217; Recommends Selling This Tech Stock</a>

AMBC

ASNS

BGXX

BNED

CLEU

CMPS

CVAC

DLTR

DOYU

FBLG

FRES

GDHG

GWRE

HLTH

JDZG

JEWL

MITQ

MLGO

MNMD

MPLN

MYND

NDRA

NVAX

NVVE

OLLI

SFIX

SGRP

SILO

SOBR

SYTA

THMO

UMAC

UNFI

VLCN

VRNT

VSTE

WKME

XTIA

Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

MakeMyTrip shares are trading higher amid volatility in Indian stocks following India's general election.

Makemytrip (MMYT) has released an update. MakeMyTrip Limited, India's premier online travel agency, has scheduled its annual shareholders meeting f...

MakeMyTrip Sets Annual Shareholder Meeting

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
In June 2010, Tesla (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/">TSLA</a>) was listed with a market valuation of $2.23 billion. Currently, the EV maker commands a market valuation of $785 billion. During this period, the company&rsquo;s market valuation has increased by more than 50% CAGR. Of course, not all companies can be Tesla. However, there are millionaire-maker <a href="https://investorplace.com/stock-types/growth-stocks/">growth stocks</a> to buy that can make investors rich.



If we look at Tesla&rsquo;s story, there are two lessons for investors. First, patience is the key to massive wealth creation. Trading good stocks is unlikely to create wealth. The key is buying and holding for the long term.



Further, there are instances of deep corrections during the journey from $2.23 billion to $785 billion. Investors need to avoid panic selling and focus entirely on the growth story and the progress in fundamentals.



With this overview, let&rsquo;s discuss seven millionaire-maker growth stocks worth considering for the next five to seven years.



<h2>Archer Aviation (ACHR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/10/achr1600-2-300x169.png" alt="Person holding cellphone with logo of American eVTOL aircraft company Archer Aviation Inc. (ACHR) on screen in front of webpage. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div>The flying car industry is at a nascent stage. However, it is <a href="https://s202.q4cdn.com/174276461/files/doc_presentations/2023/Apr/20/investor-overview_april-2023.pdf">expected to be worth</a> $1 trillion by 2040. Early movers with good execution can undoubtedly create massive wealth. Archer Aviation (NYSE:<a href="https://investorplace.com/stock-quotes/achr-stock-quote/">ACHR</a>) is an attractive bet in the eVTOL industry.



First, I would mention that investors in Archer include Stellantis (NYSE:<a href="https://investorplace.com/stock-quotes/stla-stock-quote/">STLA</a>) and United Airlines (NYSE:<a href="https://investorplace.com/stock-quotes/ual-stock-quote/">UAL</a>). The backing of blue-chip companies underscores the business&rsquo;s potential. Recently, Archer <a href="https://www.investors.archer.com/news/news-details/2024/Southwest-Airlines-Signs-Memorandum-of-Understanding-With-Archer-Aviation-to-Develop-Operational-Concepts-for-Air-Taxi-Network/default.aspx">partnered</a> with Southwest Airlines (NYSE:<a href="https://investorplace.com/stock-quotes/luv-stock-quote/">LUV</a>) to develop operational plans for electric air taxi networks utilizing Archer&rsquo;s eVTOL aircraft at California airports.



In the international markets, Archer has formed partnerships in the UAE, India and Korea to commercialize eVTOL. Therefore, Archer is setting a strong base for growth in 2025 and beyond. It&rsquo;s worth noting that the company is also expected to complete the construction of its manufacturing facility by the end of the year. This will support the production of 650 eVTOL annually and help scale up operations.



<h2>ZEEKR Intelligent Technology (ZK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/05/zk1600-1-300x169.png" alt="ZEEKR logo is seen at one of its stores in Ningbo, China. Zeekr is a premium electric automobile brand owned by the Chinese automaker, Geely Automobile Holdings. ZK stock"><div>Source: Tada Images / Shutterstock.com</div></div>Electric vehicle stocks have witnessed a significant correction due to macroeconomic headwinds, competition and trade wars. However, EV adoption will continue to increase in the coming years, and the correction is a good opportunity to accumulate quality growth stocks. ZEEKR Intelligent Technology (NYSE:<a href="https://investorplace.com/stock-quotes/zk-stock-quote/">ZK</a>) is a recently listed EV company that looks promising.



For Q1 2024, ZEEKR delivered 33,059 vehicles, up 117% yearly. Revenue for the period increased by 73% to $1.1 billion. While the company reported an operating loss of $289 million, it was lower by 29% yearly. With a healthy vehicle margin and operating leverage, I expect losses to narrow further in the coming quarters.



I must add that for the first half of the year, ZEEKR reported a 106% growth in deliveries to 87,870 vehicles. The growth is robust even amidst macroeconomic headwinds. In June, the EV company entered cooperation agreements with PT Premium Auto Prima in Indonesia and Sentinel Automotive in Malaysia. With entry into two high-potential markets, I expect robust growth to be sustained.



<h2>Tempus AI (TEM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/06/temp-stock1600-300x169.png" alt="Person holding mobile phone with logo of American health care company Tempus Labs Inc. on screen in front of web page. Focus on phone display."><div>Source: T. Schneider / Shutterstock.com</div></div>Tempus AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/tem-stock-quote/">TEM</a>) is another new listing with multi-bagger returns potential. As an overview, Tempus AI is a healthcare technology company. In the coming years, artificial intelligence is likely to impact sectors, and Tempus is unleashing the power of AI for the healthcare industry.



It&rsquo;s worth noting that the company&rsquo;s focus on research and development is yielding results. In June, the company received U.S. Food and Drug Administration clearance for <a href="https://www.tempus.com/news/tempus-receives-u-s-fda-510k-clearance-for-tempus-ecg-af-an-ai-based-algorithm-that-identifies-patients-at-increased-risk-of-afib/">Tempus ECG-AF device</a> &ldquo;that uses AI to help identify patients who may be at increased risk of atrial fibrillation/flutter.&rdquo;



Earlier this month, the Centers for Medicare &amp; Medicaid Services <a href="https://www.tempus.com/news/cms-awards-tempus-with-advanced-diagnostic-laboratory-test-adlt-status-for-its-xt-cdx-test/">granted</a> advanced diagnostic laboratory test status for the company&rsquo;s next-generation sequencing assay. For the year ended December 2023, Tempus <a href="https://investors.tempus.com/static-files/5b09c4f8-0287-4d89-ba23-a276d9e5fc0e">reported revenue</a> of $531.8 million. On a year-on-year basis, revenue increased by 65.8%. As more products are launched, Tempus is positioned to accelerate growth in the coming years.



<h2>Leonardo DRS (DRS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/07/growth-stock-hands-coins-1600-300x169.jpg" alt="Graphic of hands holding coins with growth arrows heading upward in background. hypergrowth stocks"><div>Source: shutterstock.com/Lemonsoup14</div></div>Global defense spending hit record highs of $2.44 trillion in 2023. Considering rising geopolitical tensions, defense spending growth will likely be robust. Leonardo DRS (NASDAQ:<a href="https://investorplace.com/stock-quotes/drs-stock-quote/">DRS</a>) is attractive among emerging defense companies.



It&rsquo;s worth noting that DRS stock has surged by 65% in the last 12 months. I would look at corrections for fresh exposure to the stock. Considering the company&rsquo;s focus on innovation, I am bullish on multibagger returns.



The provider of defense electronic products and systems <a href="https://investors.leonardodrs.com/static-files/b29a361b-8971-4707-8590-e382ee6027f3">reported an order backlog</a> of $7.8 billion as of Q1 2024. The order backlog has swelled by 84% year over year. A robust order intake will support revenue growth acceleration.



For Q1 2024, Leonardo reported revenue growth of 21% on a year-on-year basis to $688 million. For the same period, adjusted EBITDA was $70 million with <a href="https://investors.leonardodrs.com/news-releases/news-release-details/leonardo-drs-announces-financial-results-first-quarter-2024">EBITDA margin expanding</a> by 160 basis points to 10.2%. I expect further margin expansion on operating leverage in the next few years.



<h2>Cronos (CRON)</h2>



<a href="https://investorplace.com/wp-content/uploads/2019/06/cron.jpg"><img width="282" height="179" src="https://investorplace.com/wp-content/uploads/2019/06/cron.jpg" alt="Cronos (CRON)"></a>Some <a href="https://investorplace.com/industries/healthcare/cannabis/">cannabis stocks</a> are likely to create massive wealth for investors by the end of the decade. Even without federal legalization, the U.S. cannabis market is <a href="https://www.globenewswire.com/en/news-release/2023/03/22/2632475/0/en/U-S-Cannabis-Sales-Could-Total-71B-in-2030-Without-Federal-Legalization.html">expected to be worth</a> $71 billion. Further, Europe has a big market for medicinal cannabis, and regulations are likely to become friendlier.



Cronos (NASDAQ:<a href="https://investorplace.com/stock-quotes/cron-stock-quote/">CRON</a>) is a potential millionaire-maker growth stock to buy from the cannabis sector. I like that the company has been prudent in its spending. As of Q1 2024, Cronos had a <a href="https://ir.thecronosgroup.com/news-releases/news-release-details/cronos-group-reports-2024-first-quarter-results">cash buffer</a> of $855 million.



At the beginning of 2023, Cronos was focused on Canada and Israel. However, the company has pursued geographical expansion into new markets, including Germany, Australia and the United Kingdom. This is likely to support growth acceleration and improvement in EBITDA margin.



With the possibility of cannabis being reclassified as a Schedule III drug in the United States, I expect Cronos to pursue organic or acquisition-driven growth. Backed by strong fundamentals, Cronos is positioned for stellar growth and value creation.



<h2>MakeMyTrip (MMYT)</h2>



<div><img width="300" height="165" src="https://investorplace.com/wp-content/uploads/2017/03/mmytmsn-300x165.jpg" alt="a blurry photo of people standing in line at an airport"><div>Source: Shutterstock</div></div>MakeMyTrip (NASDAQ:<a href="https://investorplace.com/stock-quotes/mmyt-stock-quote/">MMYT</a>) stock has skyrocketed by 215% in the last 12 months. It makes sense to wait for a correction to enter. However, there is no doubt that the company will likely deliver multi-fold revenue growth by the end of the decade.



As an overview, MakeMyTrip provides online booking solutions for the travel and tourism industry in India. By 2030, Indians are expected to be the fourth-largest global travel spenders, with spending <a href="https://www.cnbc.com/2023/11/02/indian-travelers-are-set-to-be-fourth-largest-global-spenders-by-2030-.html">expected to hit $410 billion</a>. As a leading player in the industry, MakeMyTrip is positioned to benefit.



For the financial year 2024, MakeMyTrip reported the highest annual gross booking of $7.9 billion. For the same period, operating profit was $124.2 million. It&rsquo;s worth noting that MakeMyTrip reported an operating loss of $69.9 million in FY20. The recovery from the pandemic has been significant, and I expect healthy revenue growth coupled with margin expansion.



<h2>Miniso Group Holdings (MNSO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/08/miniso-mnso-1600-300x169.jpg" alt="red Miniso (MNSO) sign glowing at night"><div>Source: shutterstock.com/Hendrick Wu</div></div>I believe that Miniso Group (NYSE:<a href="https://investorplace.com/stock-quotes/mnso-stock-quote/">MNSO</a>) is an undervalued stock that&rsquo;s likely to create value in the long term. The stock of the lifestyle retailer trades at a forward P/E of 14.4 and offers a dividend yield of 2.31%. With ambitious growth plans, I expect a strong reversal for MNSO stock from current levels.



One reason for MNSO being depressed is negative sentiments related to Chinese stocks. From a financial perspective, growth has been robust and should have been associated with a rally. To put things into perspective, for Q1 2024, Miniso reported revenue growth of 26% to $515.7 million. For the same period, <a href="https://filecache.investorroom.com/mr5ir_miniso/315/MINISO%202024%20Mar%20Quarter%20ER.pdf">EBITDA margin expanded</a> by 200 basis points to 25.9%.



Stark growth is likely to continue in the next five years. Miniso <a href="https://filecache.investorroom.com/mr5ir_miniso/306/MINISO%20December%20Quarter_v6-%E6%9B%B4%E6%96%B0%E6%8C%82%E7%BD%91.pdf">plans to open</a> 900 to 1,100 new stores annually between 2024 and 2028. The company has guided revenue growth at a CAGR of more than 20%. With operating leverage, the EBITDA margin is likely to be higher than current levels. Miniso is, therefore, positioned to report healthy cash flows.



On the date of publication, Faisal Humayun did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Faisal Humayun is a senior research analyst with 12 years of industry experience in the field of credit research, equity research and financial modeling. Faisal has authored over 1,500 stock specific articles with focus on the technology, energy and commodities sector.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/2024/07/7-growth-stocks-that-can-create-millionaires-by-2030/">7 Growth Stocks That Can Create Millionaires by 2030</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Growth Stocks That Can Create Millionaires by 2030

MakeMyTrip: Dominant OTA Player In India

FMQQ ETF: The Promise Of Global Gen Z

Morgan Stanley analyst Gaurav Rateria maintained a Buy rating on Makemytrip (MMYT – Research Report) today and set a price target of $111.00. Gaura...

Makemytrip (MMYT) Receives 'Buy' Rating on Robust Volume Growth and Market Resilience

Trip.com: The Hottest Consumer Market In China

Analyst Sachin Salgaonkar from Bank of America Securities reiterated a Buy rating on Makemytrip (MMYT – Research Report) and increased the price ta...

Makemytrip's Growth and Profitability Outlook: A Buy Rating with Robust Potential

Makemytrip (MMYT) has released an update. MakeMyTrip Limited successfully conducted its annual shareholders' meeting for fiscal year 2024 on Septem...

MakeMyTrip Shareholders Approve All Resolutions

Gaurav Rateria, an analyst from Morgan Stanley, maintained the Buy rating on Makemytrip (MMYT – Research Report). The associated price target remai...

Comments

MakeMyTrip

뉴스

에 대한 최신 뉴스 MakeMyTrip (NASDAQ:MMYT) 주식

월요일, 9월 30, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌